PCRX Pacira BioSciences, Inc.

NASDAQ
$25.12

Pacira BioSciences, Inc. (PCRX) is expected to report earnings on November 5, 2026, after the market close. The consensus earnings estimate is $0.47 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -3.6% since its last earnings release on August 4, 2026.

Pacira BioSciences Beat Expectations, Lowers Guidance
Tuesday, August 4, 2026 · 4:01 PM ET
Earnings Date
3rd Quarter, Sep 2026
Nov 5
Thursday · 4:00 PM ET
Earnings Whisper
-
vs $0.47 (GAAP)
Rev est $181.42M
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $24.89

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Pacira BioSciences, Inc.

Pacira Pharmaceuticals Inc is a specialty pharmaceutical company. The Company is engaged in the development, commercialization and manufacture of proprietary pharmaceutical products for use in hospitals and ambulatory surgery centers.

Sector

Healthcare

Industry

Biotechnology

Held By 6 ETFs, by dollar flow

Charts powered in part by Lightweight Charts™ by TradingView.